BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics
BBIO Stock Summary
- BBIO's went public 1.82 years ago, making it older than merely 2.54% of listed US stocks we're tracking.
- BBIO's price/sales ratio is 998.76; that's higher than the P/S ratio of 99.2% of US stocks.
- As for revenue growth, note that BBIO's revenue has grown -79.66% over the past 12 months; that beats the revenue growth of merely 1.87% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to BridgeBio Pharma Inc are SNDX, SRRA, INO, SVRA, and CKPT.
- BBIO's SEC filings can be seen here. And to visit BridgeBio Pharma Inc's official web site, go to bridgebio.com.
BBIO Stock Price Chart Interactive Chart >
BBIO Price/Volume Stats
| Current price | $55.90 | 52-week high | $73.50 |
| Prev. close | $55.31 | 52-week low | $26.17 |
| Day low | $54.23 | Volume | 426,000 |
| Day high | $57.14 | Avg. volume | 990,283 |
| 50-day MA | $62.74 | Dividend yield | N/A |
| 200-day MA | $49.06 | Market Cap | 8.33B |
BridgeBio Pharma, Inc. (BBIO) Company Bio
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Latest BBIO News From Around the Web
Below are the latest news stories about BridgeBio Pharma Inc that investors may wish to consider to help them evaluate BBIO as an investment opportunity.
BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven ConditionsPALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a focus on oncology and neurology. “UC San Diego is a leading research institution with a top pharmacology department and a strong profile in neurology and oncology. By leveraging their expertise through our collaboration partnership, we hope to advance discoveries into potential treatments as quickly and safely as possible,” said BridgeBio founder and CEO Neil Kumar, Ph.D. Under this partnership, BridgeBio and UC San Diego will collaborate on identifying research programs with strong potential f... |
BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven DiseasesPALO ALTO, Calif. and SACRAMENTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers. “UC Davis is a top-tier research university and we feel honored to get the chance to collaborate closely with the talented team there as we work to discover, create, test and deliver breakthrough medicines for people who are suffering from genetic diseases,” said BridgeBio founder and CEO Neil Kumar, Ph.D. Under the agreement, the BridgeBio team will work closely with investigators at UC Davis to seek and evaluate potential research projects in genetic disease an... |
BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven CancersPALO ALTO, Calif. and BUFFALO, N.Y., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers. “We are honored to begin collaborating with Roswell Park, which is renowned for its excellence in cancer research and its mission to set the gold standard for treating patients with genetically driven cancers,” said BridgeBio CEO and founder Neil Kumar, Ph.D. Under the partnership, BridgeBio will work with scientists at Roswell Park Comprehensive Cancer Center to evaluate new research and development opportunities in oncology that have promise to advance and potentially provide clinical benefit for ... |
BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven DiseasesPALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with genetically driven conditions. “We feel privileged to have the opportunity to work with OHSU to focus on developing potential therapies for diseases with clear genetic drivers and severe unmet need,” said BridgeBio founder and CEO Neil Kumar, Ph.D. “OHSU was one of the first research institutions we connected with in the early days of BridgeBio, and we look forward to deepening our relationship through close collaboration with their scientists as we strive to help patients together.” This arrangement builds on fi... |
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and CancersTORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers into potential treatments for patients. “The Lundquist Institute is renowned for its scientific research and drug discoveries, and we look forward to developing a close relationship with their talented scientists in the hope of translating their discoveries into medicines with meaningful benefit for patients,” said BridgeBio CEO and Founder Neil Kumar, Ph.D. Under the established two-year partnership, BridgeBio will work closely with The Lundquist Institute researchers to identify programs that... |
BBIO Price Returns
| 1-mo | -8.76% |
| 3-mo | -19.55% |
| 6-mo | 40.95% |
| 1-year | 88.22% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -21.39% |
| 2020 | 102.88% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...